Athersys (ATHX) MultiStem Granted Orphan Drug Designation by FDA for Hurler's Syndrome Treatment
Tweet Send to a Friend
Athersys, Inc. (Nasdaq: ATHX) announced that MultiStem®, Athersys' proprietary cell therapy, has been granted orphan drug designation by the U.S ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
